Today’s guest post comes from Angie Franks, CEO at Kalderos.
Angie examines how data fragmentation contributes to inefficiencies in drug discount programs and the broader gross-to-net bubble—the widening difference between a drug’s revenue at list prices and what manufacturers actually receive. Angie outlines how better access to consistent, claims-level data could help reduce waste, improve program integrity, and enhance collaboration among stakeholders in the drug channel.
To learn more, download Following the Dollars: Why 340B Reform Is a Data-Driven Necessity.
Read on for Angie’s insights.
Read more »
Source: Post feed
